Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson’s disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson’s disease
Authors
Keywords
-
Journal
BRAIN
Volume 144, Issue 4, Pages 1127-1137
Publisher
Oxford University Press (OUP)
Online
2021-01-25
DOI
10.1093/brain/awab015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats
- (2019) Ghada A. Badawi et al. NEUROTOXICITY RESEARCH
- Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
- (2019) Vladimer Darsalia et al. Frontiers in Neurology
- The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect
- (2019) Konstantinos Makrilakis International Journal of Environmental Research and Public Health
- Diabetes mellitus and Parkinson disease
- (2018) Gennaro Pagano et al. NEUROLOGY
- Putaminal dopamine depletion in de novo Parkinson's disease predicts future development of wearing-off
- (2018) Su Jin Chung et al. PARKINSONISM & RELATED DISORDERS
- Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
- (2018) Bassam M. Ayoub et al. Scientific Reports
- Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin
- (2018) Grazyna Lietzau et al. Acta Neuropathologica Communications
- The Pattern of Striatal Dopamine Depletion as a Prognostic Marker in De Novo Parkinson Disease
- (2018) Seok Jong Chung et al. CLINICAL NUCLEAR MEDICINE
- Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease
- (2018) Seok Jong Chung et al. PARKINSONISM & RELATED DISORDERS
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Parkinson’s Disease Severity at 3 Years Can Be Predicted from Non-Motor Symptoms at Baseline
- (2017) Alba Ayala et al. Frontiers in Neurology
- Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease
- (2017) Ghada A. Badawi et al. INFLAMMOPHARMACOLOGY
- Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease
- (2016) M. Petrou et al. ACADEMIC RADIOLOGY
- Increased Dipeptidyl Peptidase-4 Activity Is Associated With High Prevalence of Depression in Middle-Aged and Older Adults
- (2016) Tianpeng Zheng et al. JOURNAL OF CLINICAL PSYCHIATRY
- Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer’s Disease
- (2016) Jayasankar Kosaraju et al. MOLECULAR NEUROBIOLOGY
- Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study
- (2016) Per Svenningsson et al. MOVEMENT DISORDERS
- Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline
- (2015) V. A. Gault et al. DIABETES OBESITY & METABOLISM
- Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways
- (2015) Rania M. Abdelsalam et al. JOURNAL OF NEUROCHEMISTRY
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
- (2015) W. Liu et al. NEUROSCIENCE
- Type 2 diabetes as a protein misfolding disease
- (2015) Abhisek Mukherjee et al. TRENDS IN MOLECULAR MEDICINE
- Cerebellum-specific 18F-FDG PET analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia
- (2014) Jungsu S. Oh et al. NEUROREPORT
- Diagnosis and Classification of Diabetes Mellitus
- (2013) DIABETES CARE
- How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale
- (2013) Glenn T. Stebbins et al. MOVEMENT DISORDERS
- Diabetes is associated with postural instability and gait difficulty in Parkinson disease
- (2013) Vikas Kotagal et al. PARKINSONISM & RELATED DISORDERS
- Shared dysregulated pathways lead to Parkinson's disease and diabetes
- (2013) Jose A. Santiago et al. TRENDS IN MOLECULAR MEDICINE
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
- (2012) Kerry Hunter et al. BMC NEUROSCIENCE
- Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia
- (2012) Peter Röhnert et al. Journal of Neuroinflammation
- Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy
- (2012) M. Oh et al. JOURNAL OF NUCLEAR MEDICINE
- Clinical features of Parkinson disease when onset of diabetes came first: A case-control study
- (2012) E. Cereda et al. NEUROLOGY
- Diabetes and Risk of Parkinson's Disease
- (2011) Q. Xu et al. DIABETES CARE
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
- (2010) Olivia J. Phung JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical measures of progression in Parkinson's disease
- (2010) Werner Poewe MOVEMENT DISORDERS
- Systematic review of levodopa dose equivalency reporting in Parkinson's disease
- (2010) Claire L. Tomlinson et al. MOVEMENT DISORDERS
- Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats
- (2009) Holger Fuchs et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease
- (2009) Paula L. McClean et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice
- (2009) Michele D’Amico et al. EXPERIMENTAL GERONTOLOGY
- Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
- (2009) Sehee Kim et al. JOURNAL OF ENDOCRINOLOGY
- An adaptation of the Korean mini-mental state examination (K-MMSE) in elderly Koreans: Demographic influence and population-based norms (the AGE study)
- (2007) Changsu Han et al. ARCHIVES OF GERONTOLOGY AND GERIATRICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started